Home>Topics>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR AZN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. AstraZeneca hit after psoriasis drug linked to suicide fears

      Headlines

      Tue, 26 May 2015

      LONDON (Reuters) - AstraZeneca 's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller.

    2. AstraZeneca hit after psoriasis drug linked to suicide fears

      Headlines

      Tue, 26 May 2015

      LONDON, May 26 (Reuters) - AstraZeneca 's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a...

    3. UPDATE 2-Amgen ends partnership with AstraZeneca on psoriasis drug

      Headlines

      Fri, 22 May 2015

      May 22 (Reuters) - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.

    4. Amgen ends collaboration with AstraZeneca on inflammation drug

      Headlines

      Fri, 22 May 2015

      May 22 (Reuters) - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in subjects of a trial.

    5. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

      Video Reports

      Thu, 21 May 2015

      TICKER:RHHBY] Roche (RHHBY), and [TICKER: AZN ] AstraZeneca ( AZN ) as well. So, those are the four names that ..... positioned--after that Roche and [TICKER: AZN ] AstraZeneca are very well positioned. Merck is well in the

      AZN AstraZeneca found at 0:57, 4:19

      pack is [TICKER:BMY] Bristol-Myers (BMY). Along with Bristol, there's Merck (MRK), [TICKER:RHHBY] Roche (RHHBY), and [TICKER: AZN ] AstraZeneca AZN as well. So, those are the four names that we see as really leading this next wave of innovation in immuno-oncology. Coffina:
      best positioned for combination therapy are, again, Bristol--very well positioned--after that Roche and [TICKER: AZN ] AstraZeneca are very well positioned. Merck is well in the lead with immuno-oncology but doesn't have quite as many combinations as those other three companies have. Coffina: Great. Thanks for joining me, Damien. Conover: Matt, thanks for having me. Coffina: So, in conclusion, we think immuno-oncology is a particularly promising area for growth for pharmaceutical firms and that Bristol-Myers and Merck look like some of the best investment opportunities. [TICKER: AZN ] AstraZeneca and Roche are also toward the forefront of developing these drugs. For Morningstar StockInvestor , I'm Matt Coffina. Thanks for joining us.
    6. AstraZeneca to invest $285 million in Swedish biotech drug factory

      Headlines

      Mon, 18 May 2015

      LONDON (Reuters) - AstraZeneca is investing $285 million to expand biotech drug manufacturing in Sweden as the company bets on the future of high-tech medicine for future growth.

    7. UPDATE 1- AstraZeneca to invest $285 mln in Swedish biotech drug factory

      Headlines

      Mon, 18 May 2015

      LONDON, May 18 (Reuters) - AstraZeneca is investing $285 million to expand biotech drug manufacturing in Sweden as the company bets on the future of high-tech medicine for future growth.

    8. CORRECTED-BRIEF- Astrazeneca to invest $285 mln in biologics facility in Sweden

      Headlines

      Mon, 18 May 2015

      * To invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio

    9. AstraZeneca to invest $285 mln in Swedish biotech factory

      Headlines

      Mon, 18 May 2015

      LONDON, May 18 (Reuters) - AstraZeneca is investing $285 million to expand biotech drug manufacturing in Sweden as the company bets on the future of high-tech medicine for future growth.

    10. BRIEF- AstraZeneca to invest in biologics manufacturing facility in Sweden

      Headlines

      Mon, 18 May 2015

      * Astrazeneca to invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio

    « Prev12345Next »
    Content Partners